74%
de las cuentas minoristas pierden dinero al operar CFDs con este proveedor.
Las inversiones conllevan riesgos y no son adecuadas para todos los inversores. Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
74%
de inversores minoristas pierden dinero cuando operan con CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs, y si puedes permitirte asumir el alto riesgo de perder tu dinero.
74%
de las cuentas minoristas pierden dinero al operar CFDs con este proveedor.
Las inversiones conllevan riesgos y no son adecuadas para todos los inversores. Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
74%
de inversores minoristas pierden dinero cuando operan con CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs, y si puedes permitirte asumir el alto riesgo de perder tu dinero.
Español (Latinoamérica)
CytoSorbents Corp
Abierto
SectorSalud
1.08 1.89
Resumen
Variación precio
24h
Mínimo
1.06
Máximo
1.12
Ingresos | -5.5M -7.9M |
|---|---|
Ventas | 538K 9.2M |
BPA | -0.144 |
Margen de beneficio | -86.158 |
Empleados | 149 |
EBITDA | -4.6M -8.5M |
Recomendaciones | Neutral |
|---|---|
Estimación a 12 meses | -13.79% downside |
Próximas Ganancias | 8 may 2025 |
|---|
Capitalización de Mercado | 5.8M 68M |
|---|---|
Apertura anterior | -0.81 |
Cierre anterior | 1.08 |
Puntuación técnica
By Trading Central
Confianza
Very Strong Bullish Evidence
CytoSorbents Corp Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
CytoSorbents Corp Esperado
Precio Objetivo
By TipRanks
-13.79% caída
Estimación a 12 meses
Media 1 USD -13.79%
Máximo 1 USD
Mínimo 1 USD
De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CytoSorbents Corp Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de CytoSorbents Corp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
